Novartis | NVS - الربح قبل الضريبة





الربح قبل الضريبة تغيير تاريخ
AbbVie USD 7.61B 2.04B 2026-06
Amgen USD 2.08B 570M 2026-03
AstraZeneca USD 4.81B 894M 2026-06
Bausch Health Companies USD 348M 1.7B 2026-06
Biogen USD 647.3M 269.6M 2026-06
Bristol-Myers Squibb USD 4.99B 1.75B 2026-06
Canopy Growth CAD -157.96M 95.71M 2026-03
Corcept Therapeutics USD -44.72M 54.62M 2026-03
Drreddys Laboratories INR 2B 13.43B 2026-03
Eli Lilly USD 8.85B 583.8M 2026-03
Gilead Sciences USD -7.53B 10.11B 2026-06
GlaxoSmithKline GBP 2.68B 532M 2026-06
Glaxosmithkline GBP 2.14B 312M 2026-03
J&J USD 8.66B 839M 2026-06
Merck USD -3.53B 6.95B 2026-03
Novartis USD 4.27B 430M 2026-06
Novartis USD 3.84B 1.33B 2026-03
Pacira USD 5M 4.43M 2026-03
Perrigo USD -408.5M 923.2M 2026-03
Pfizer USD -653M 5.84B 2026-06
Phibro Animal Health USD 38.62M 1.26M 2025-12
Prestige Brands USD 61.81M 7.32M 2025-12
Roche Holding CHF 11.17B 6.38B 2026-06
Sanofi EUR 837M 1.17B 2026-06
Sanofi EUR 2B 3.16B 2026-03
Supernus Pharmaceuticals USD -57.65M 51.7M 2026-06
Zoetis USD 761M 126M 2025-12